Alimentary Pharmacology & Therapeutics · 1987 · 17 citations · 7 references
MedicinePharmacologyPharmacotherapyBioavailabilityClinical PharmacologyGastrointestinal PharmacotherapyAcid-base ManagementGastrointestinal PharmacologyPeptic Ulcer DiseasePeptic Ulcer PharmacotherapyUlcer ManagementAcid Secretion InhibitionDuodenal Ulcer ManagementGastric Acid-base BalanceGastric Ph AssessmentMucosal Barrier ProtectionMucosal ProtectionMucosal Protective TherapyUlcer Healing Pharmacodynamics
The effects of bedtime 70 micrograms and twice daily 35 micrograms doses of enprostil on 24-hour intragastric acidity were investigated in nine duodenal ulcer patients in remission. Median nocturnal acidity decreased significantly by 30% with 35 micrograms twice daily, and by 48% with 70 micrograms at bedtime. In a clinical trial using bedtime dosing, 102 duodenal ulcer patients randomly received either ranitidine 300 mg or enprostil 70 micrograms. More ulcers healed after 4 and 8 weeks treatment with ranitidine than with enprostil (76% ranitidine vs 52% enprostil, at 4 weeks p = 0.0065 and 94% vs 68%, respectively at 8 weeks, P = 0.0007). However, 6 months after cessation of treatment there was no material difference in overall outcome. Despite combining mucosal protection with acid inhibition enprostil treatment conferred no advantage over simple acid inhibition.
7
PROSTAGLANDINS FOR PEPTIC ULCER: A PROMISE UNFULFILLED
Christopher J. Hawkey, R P Walt · The Lancet · 1986 · 88 citations
Enprostil and ranitidine in duodenal ulcer healing: double blind comparative trial.
K. Lauritsen, L. Laursen, Troels Havelund et al. · BMJ · 1986 · 54 citations · Full text